ERBB2 and ductal breast carcinoma in situ: The National Surgical Adjuvant Breast and Bowel Project (NSABB P)-43 trial investigated the efficacy of adding trastuzumab following surgery and radiation therapy for HER2-positive DCIS patients and concluded that this was not effective [10,20].